日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

西南肿瘤协作组 S0826:SCH 727965(NSC 727135,dinaciclib)治疗 IV 期黑色素瘤患者的 II 期临床试验

Lao, Christopher D; Moon, James; Ma, Vincent T; Fruehauf, John P; Flaherty, Lawrence E; Bury, Martin J; Martin, William G; Gross, Howard; Akerley, Wallace; Hopkins, Judith O; Patel, Sapna P; Sondak, Vernon K; Ribas, Antoni

A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer

多西他赛联合番茄红素治疗转移性去势抵抗性前列腺癌的II期研究

Zhuang, Eric; Uchio, Edward; Lilly, Michael; Zi, Xiaolin; Fruehauf, John P

BIOM-15. SUBVENTRICULAR ZONE INVOLVEMENT IS ASSOCIATED WITH WORSE OUTCOME IN GLIOMA WHO GRADE II INDEPENDENT OF MOLECULAR MARKERS

BIOM-15. 脑室下区受累与II级胶质瘤患者预后不良相关,且与分子标志物无关。

Randall, Leslie M; Monk, Bradley J; Moon, James; Parker, Ricardo; Al-Ghazi, Muthana; Wilczynski, Sharon; Fruehauf, John P; Markman, Maurie; Burger, Robert A; Karschnia, Philipp; Weller, Jonathan; Blobner, Jens; Stoecklein, Veit M; Dorostkar, Mario M; Rejeski, Kai D; Forbrig, Robert; Niyazi, Maximilian; von Baumgarten, Louisa; Dietrich, Jorg; Tonn, Joerg-Christian; Thon, Niklas

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

帕唑帕尼联合紫杉醇治疗转移性黑色素瘤患者的II期研究

Fruehauf, John P; El-Masry, Monica; Osann, Katherine; Parmakhtiar, Basmina; Yamamoto, Maki; Jakowatz, James G

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma

BEAM:一项随机 II 期研究,旨在评估贝伐珠单抗联合卡铂和紫杉醇治疗既往未接受治疗的晚期黑色素瘤患者的疗效。

Kim, Kevin B; Sosman, Jeffrey A; Fruehauf, John P; Linette, Gerald P; Markovic, Svetomir N; McDermott, David F; Weber, Jeffrey S; Nguyen, Hoa; Cheverton, Peter; Chen, Daniel; Peterson, Amy C; Carson, William E 3rd; O'Day, Steven J

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma

一项评估多西他赛、长春瑞滨和粒细胞-巨噬细胞集落刺激因子(GM-CSF)治疗IV期黑色素瘤的II期临床试验

Eroglu, Zeynep; Kong, Kevin M; Jakowatz, James G; Samlowski, Wolfram; Fruehauf, John P

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

贝伐单抗治疗复发性和持续性卵巢癌或腹膜癌的妇科肿瘤组 II 期试验中的预测性和预后性血管生成标志物

Han Ernest S, Burger Robert A, Darcy Kathleen M, Sill Michael W, Randall Leslie M, Chase Dana, Parmakhtiar Basmina, Monk Bradley J, Greer Benjamin E, Connelly Patrick, Degeest Koen, Fruehauf John P

Targeted therapy in ovarian cancer

卵巢癌的靶向治疗

Willmott, Lyndsay J; Fruehauf, John P

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

高危早期宫颈癌血管生成标志物:妇科肿瘤协作组研究

Randall, Leslie M; Monk, Bradley J; Darcy, Kathleen M; Tian, Chunqiao; Burger, Robert A; Liao, Shu-Yuan; Peters, William A; Stock, Richard J; Fruehauf, John P